WHO estimates that more than 700.000 people die every year as a result of drug-resistant infections. To tackle this problem and change the current trend, it is necessary to design advanced strategies for drug discovery and to promote early-stage research activities finalized at the development of new drugs. In this study, we present the results of the preliminary screening of a library of microorganisms, collected from different environmental settings. Approximately 300 strains of the culture collection were tested on solid medium for inhibition of growth of three tester species, namely Bacillus subtilis, Escherichia coli and Staphylococcus aureus. One of the active strains, MES18, was classified as a Bacillus spp. by means of small-subunit rRNA gene sequencing. To identify the compound(s) responsible for this inhibitory activity, MES18 cells were grown in liquid medium at 30°C and samples were taken at different time points over a period of 12 days. The supernatants obtained from the fermentation media were subjected to fractionation by chromatography on reversed-phase column and all the eluted compounds were assayed for their ability to repress the growth of tester strains. This approach allowed us to identify the fractions containing the bioactive compound(s) and to establish that the production of these secondary metabolites reached a maximum during the idiophase of the cell culture, when cell growth and replication decline. Further analyses to identify the physical-chemical features of the compound(s) produced by this strain using HPLC coupled to mass-spectrometry are currently ongoing.
|Titolo:||Screening an archetypal collection of microorganisms for the presence of unexplored antimicrobial compounds.|
|Data di pubblicazione:||2016|
|Appare nelle tipologie:||Poster atto convegno su volume|